Blinatumomab

Generic Name
Blinatumomab
Brand Names
Blincyto
Drug Type
Biotech
Chemical Formula
-
CAS Number
853426-35-4
Unique Ingredient Identifier
4FR53SIF3A
Background

Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker. CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostly expressed on the surface of malignant B-cells. Since b...

Indication

Blinatumomab is indicated for the treatment of adults and children with relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL). It is also indicated in adults and children for the treatment of CD19-positive B-cell precursor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to...

Associated Conditions
Precursor B-lymphoblastic leukaemia acute, Refractory B-cell precursor acute lymphoblastic leukemia, Relapsed B cell precursor Acute lymphoblastic leukemia
Associated Therapies
-

A Study of OnCARlytics (CF33-CD19) in Combination with Blinatumomab in Adults with Advanced or Metastatic Solid Tumors (OASIS)

First Posted Date
2023-10-02
Last Posted Date
2024-12-16
Lead Sponsor
Imugene Limited
Target Recruit Count
33
Registration Number
NCT06063317
Locations
🇺🇸

City of Hope, Duarte, California, United States

🇺🇸

Emory Winship Cancer Institute, Atlanta, Georgia, United States

🇺🇸

Northwestern, Chicago, Illinois, United States

and more 4 locations

Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT

First Posted Date
2023-09-29
Last Posted Date
2024-05-06
Lead Sponsor
Goethe University
Target Recruit Count
220
Registration Number
NCT06061094
Locations
🇩🇪

Department of Medicine, Hematology and Oncology, Goethe University Hospital Frankfurt, Frankfurt, Germany

Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

First Posted Date
2023-09-26
Last Posted Date
2024-10-24
Lead Sponsor
Amgen
Target Recruit Count
18
Registration Number
NCT06054113
Locations
🇨🇳

Childrens Hospital of Chongqing Medical University, Chongqing, Chongqing, China

🇨🇳

Suzhou Kowloon Hospital, Suzhou, Jiangsu, China

🇨🇳

Childrens Hospital of Shanghai, Shanghai, Shanghai, China

and more 1 locations

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

First Posted Date
2023-05-08
Last Posted Date
2024-11-25
Lead Sponsor
Tanja Andrea Gruber
Target Recruit Count
90
Registration Number
NCT05848687
Locations
🇺🇸

Phoenix Children's Hospital, Phoenix, Arizona, United States

🇺🇸

Arkansas Children's Hospital, Little Rock, Arkansas, United States

🇺🇸

Children's Hospital Los Angeles, Los Angeles, California, United States

and more 22 locations

Minimal Residual Disease Quantification by Next-generation Sequencing in Pediatric B-ALL Children Patients Treated With Blinatumomab Consolidation

Not yet recruiting
Conditions
First Posted Date
2023-05-01
Last Posted Date
2023-05-01
Lead Sponsor
Xiaojun Xu
Target Recruit Count
20
Registration Number
NCT05837689

Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALL

First Posted Date
2022-09-29
Last Posted Date
2022-09-29
Lead Sponsor
The First Affiliated Hospital of Soochow University
Target Recruit Count
80
Registration Number
NCT05559450
Locations
🇨🇳

The first affiliated hospital of Soochow University, Suzhou, Jiangsu, China

Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALL

Phase 2
Completed
Conditions
Interventions
First Posted Date
2022-09-27
Last Posted Date
2024-08-13
Lead Sponsor
Chen Suning
Target Recruit Count
35
Registration Number
NCT05557110
Locations
🇨🇳

The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, Jiangsu, China

Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia

First Posted Date
2022-08-29
Last Posted Date
2024-12-13
Lead Sponsor
Northside Hospital, Inc.
Target Recruit Count
20
Registration Number
NCT05519579
Locations
🇺🇸

Northside Hospital, Atlanta, Georgia, United States

Interfant-21 Treatment Protocol for Infants Under 1 Year with KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia

First Posted Date
2022-04-14
Last Posted Date
2024-10-04
Lead Sponsor
Princess Maxima Center for Pediatric Oncology
Target Recruit Count
160
Registration Number
NCT05327894
Locations
🇦🇺

North Adelaide- Womens and Childrens Hospital, Adelaide, Australia

🇦🇺

Sydney Childrens Hospital, Sydney, Australia

🇦🇺

The Childrens Hospital at Westmead, Westmead, Australia

and more 56 locations
© Copyright 2024. All Rights Reserved by MedPath